Rafael logo.png
Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif.
27 sept. 2021 08h00 HE | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced that the...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue
01 déc. 2020 12h05 HE | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) --  Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft
01 déc. 2020 09h00 HE | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it...
Rafael_Pharma-Logo+Slogan.png
UPDATED RELEASE: Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
09 janv. 2019 13h15 HE | Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of patient...